Antares Pharma Announces Additional Patent Coverage for OTREXUP

Antares Pharma, Inc.

today announced the issuance of U.S. Patents RE44846 and RE44847. These patents are reissued versions of U.S. Patents 7,744,582, and 7,776,015. Tracing back to inventions made in the late 1990's, the patents capture innovations in the field of auto injectors that originally established Antares Pharma's position as a leader and innovator in medical injection device technology. Importantly, these patents add protection to OTREXUP as well as Antares' pipeline products. Antares is taking steps to supplement the current Orange Book listings related to OTREXUP. The overall Antares patent portfolio coverage exemplifies the Company's intellectual property strategy of obtaining patents that are generally directed toward devices, combination products and methods for delivering injectable drugs, which the Company has earned on its filed inventions. Paul K. Wotton, Ph.D., President and Chief Executive Officer, stated, “I am very pleased with the issuance of these new patents which have further strengthened the intellectual property protection for OTREXUP. They represent an important milestone in achieving our goal of protecting our innovation and commercial potential of OTREXUP, our first marketed product as well as for all of our current and future auto injector pipeline projects.” Dr. Wotton continued, “As an originator in the field of auto injector technology, we believe that it is important to build on our patent estate in order to enhance and protect the value of our inventions.”